Relative biological effectiveness and cell-killing efficacy of continuous low-dose-rate 125I seeds on prostate carcinoma cells in vitro

Integrative Cancer Therapies

Volumn 9, Issue 1, 2010, Pages 59-65

  Liao, Anyan ^a   Wang, Junjie ^a   Wang, Jidong ^a   Zhuang, Hongqing ^a   Zhao, Yong ^b  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

125I seeds; Bcl 2; Caspase 3; Cell apoptosis; Cell cycle; Cell proliferation; PC3 cell

Indexed keywords

CASPASE 3; COBALT 60; IODINE 125; PROTEIN BCL 2; COBALT; RADIOACTIVE IODINE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE G2 PHASE; CELL KILLING; CELL PROLIFERATION; COBALT THERAPY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GAMMA RADIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IRRADIATION; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; RADIATION DOSE; THERAPY EFFECT; CARCINOMA; CELL CYCLE; DRUG ADMINISTRATION; EVALUATION; PATHOLOGY; PROSTATE TUMOR; RADIATION EXPOSURE; RADIATION RESPONSE; RELATIVE BIOLOGIC EFFECTIVENESS; TREATMENT OUTCOME; TUMOR CELL CULTURE;

APOPTOSIS; CARCINOMA; CELL CYCLE; CELL PROLIFERATION; COBALT RADIOISOTOPES; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG ADMINISTRATION SCHEDULE; GAMMA RAYS; HUMANS; IODINE RADIOISOTOPES; MALE; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RELATIVE BIOLOGICAL EFFECTIVENESS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 77953948936     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735409357758     Document Type: Article

References (41)

1. Yu Y., Anderson L., Li ZF, et al. Permanent prostate seed implant brachytherapy: Report of the American Association of Physicists in Medicine Task Group No. 64. Med Phys. 2005 ; 26: 2054-2076.
2. Harrison LB Application of brachytherapy in head and neck cancer. Semin Surg Oncol. 1997 ; 13: 177-184.
3. Purohit RS, Shinohara K., Meng MV, Carroll PR Imaging clinically localized prostate cancer. Urol Clin North Am. 2003 ; 30: 279-293.
4. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun MJ Cancer statistics. CA Cancer J Clin. 2003 ; 53: 5-26.
5. 125I and a review of the literature. Int J Radiat Oncol Biol Phys. 1991 ; 21: 451-457.
6. Nath R., Anderson LL, Luxton G., Weaver KA, Wilianson JF, Meigooni AS Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys. 1995 ; 22: 209-234.
7. Reniers B., Vynckier S., Verhaegen F. Theoretical analysis of microdosimetric spectra and cluster formation for Pd-103 and I-125 photon emitters. Int J Radiat Oncol Biol Phys. 2004 ; 49: 3781-3795.
8. Yue N., Chen Z., Nath R. Edema-induced increase in tumour cell survival for I-125 and Pd-103 prostate permanent seed implants a mathematical model. Int J Radiat Oncol Biol Phys. 2005 ; 47: 1185-1204.
9. 192Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: a phase II trial. Radiother Oncol. 2006 ; 79: 329-334.
10. Merrick GS, Butler WM, Galbreath RW, Lief JH Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys. 2001 ; 51: 41-48.
11. 125I brachytherapy. Int J Radiat Oncol Biol Phys. 2001 ; 51: 31-40.
12. Rivard MJ, Butler WM, Devlin PM, et al. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103. Brachytherapy. 2007 ; 6: 34-37.
13. Armpilia CI, Dale RG, Coles IP, et al. The determination of radiobiologically optimized half-lives for radio nuclides used in permanent brachytherapy in plants. Int J Radiat Oncol Biol Phys. 2003 ; 55: 378-385.
14. Aird G., Folkard M., Mayes CR, Bownes PJ, Lawson JM, Joiner MC A purpose built iodine-125 plaque for low dose rate low energy irradiation of cell lines in vitro. Br J Radiol. 2001 ; 74: 56-61.
15. Ling CC, Li WX, Anderson LL The relative biological effectiveness of I-125 and Pd-103. Int J Radiat Biol Phys. 1995 ; 32: 373-378.
16. Sambrook J., Russell D. Molecular Cloning: A Laboratory Manual. 3 rd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press ; 2000: 1235-1262.
17. King CR, Dipetrillo TA, Wazer DE Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models. Int J Radiat Oncol Biol Phys. 2001 ; 46: 165-172.
18. Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland. Int J Radiat Oncol Biol Phys. 2002 ; 52: 664-673.
19. 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: a dosimetric point of view. Radiat Res. 2006 ; 78: 47-52.
20. Wang JZ, Mayr NA, Nag S., et al. Effect of edema relative biological effectiveness and dose heterogeneity on prostate brachytherapy. Med Phys. 2006 ; 33: 1025-1032.
21. 60Co gamma rays. Int J Radiat Oncol Biol Phys. 2005 ; 63: 224-229.
22. 125I brachytherapy seed with characteristic X rays from its constitutive materials. Med Phys. 2002 ; 29: 1397-1402.
23. Mitchell R., Joiner C. Effect of subsequent acute-dose irradiation on cell survival in vitro following low dose-rate exposures. Int J Radiat Biol. 2002 ; 78: 981-990.
24. Scott SL, Gumerlock PH, Beckett L., Goldberq Z. Survival and cell cycle kinetics of human prostate cancer cell lines after single and multifraction exposures to ionizing radiation. Int J Radiat Oncol Biol Phys. 2004 ; 59: 219-227.
25. Enns L., Bogen KT, Wizniak J., Murtha AD, Weinfeld M. Low-dose radiation hypersensitivity is associated with p53-dependent apoptosis. Mol Cancer Res. 2004 ; 2: 557-566.
26. Joiner MC, Marples B., Lambin P., Short SC, Turesson I. Low-dose hypersensitivity: current status and possible mechanisms. Int J Radiat Oncol Biol Phys. 2001 ; 49: 379-389.
27. Nakamura H., Yasui Y., Saito N., Tachibana A., Komatsu K., Ishizaki K. DNA repair defect in AT cells and their hypersensitivity to low-dose-rate radiation. Radiat Res. 2006 ; 165: 277-282.
28. Collis SJ, Schwaninger JM, Ntambi AJ, et al. Evasion of early cellular response mechanisms following low level radiation-induced DNA damage. J Biol Chem. 2004, 279: 49624-49632.
29. Carlsson J., Håkansson E., Eriksson V., et al. Early effect of low dose-rate radiation on cultured tumor cells. Cancer Biother Radiopharm. 2003 ; 18: 663-670.
30. Krueqer SA, Joiner MC, Weinfeld M., Piasentin E., Marples B. Role of apoptosis in low-dose hyper-radiosensitivity. Radiat Res. 2007 ; 167: 260-267.
31. Michael, Wang L., Handly JR Ionizing radiation-induced mitogen-activated protein (MAP) kinase activation in DU-145 prostate carcinoma cells: MAP kinase inhibition enhances radiation-induced cell killing and G2/M-phase arrest. Radiat Res. 2000 ; 153: 371-383.
32. Tang DG, Li L., Chopra DP, Porter AT Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation evasion of apoptosis,and the role of apoptosis proteins. Cancer Res. 1998 ; 58: 3466-3479.
33. Lowe SL, Rubinchik S., Honda T., Mcdonnell TJ, Dong JY, Norris JS Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells. Gene Ther. 2001 ; 818: 1363-1371.
34. Shi CJ, Zeng HH, Li HW, Yang FG, Wu XQ, Yu LZ Induction of apoptosis in prostate cancer cell line PC-3 by BBSKE, a novel organoselenium compound, and its effect in vivo [in Chinese]. Zhonghua Yi Xue Za Zhi. 2003 ; 83: 1984-1988.
35. Szostak MJ, Kaur P., Amin P., Jacobs SC, Kyprianou N. Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytheray. J Urol. 2001 ; 165: 2126-2130.
36. Bondar VM, McConkey DJ Anoikis is regulated by BCL-2-independent pathways in human prostate carcinoma cells. Prostate. 2002 ; 51: 42-49.
37. Keledjian K., Kyprianou N. Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2. J Urol. 2003 ; 169: 1150-1156.
38. Mirzaie-Joniani H., Eriksson D., Sheikholvaezin A., et al. Apoptosis induced by low-dose-rate radiation. Cancer. 2002 ; 94: 1210-1214.
39. Kroger LA, Denardo GL, Gumerlock PH, et al. Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-217-BAT-Lym-l radioimmunotherapy. Cancer Biother Radiopharm. 2001 ; 16: 213-225.
40. Yacoub A., Mckinstry R., Hinman D., Chung T., Dent P., Hagan MP Epidermal growth factor and ionizing radiation up-regulate the DNA repair gens XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res. 2003 ; 159: 439-452.
41. Bromfield GP, Meng A., Warde P., Bristow RG Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill. Prostatic Dis. 2003 ; 61: 73-85.